Alfonso Felipe

@Brandon_Beaber So tired of this… as if MRI could show what really happens in MS. None of these DMTs target underlying neurodegeneration, the real MS. 🤦🏻

Different approaches to the treatment of multiple sclerosis with disease modifying therapy in graphical form. pubmed.ncbi.nlm.nih.gov/41925508/

@GS1_US i'm trying to create a ticket to get support, but my portal says 'access denied'. How can I get help?

@Brandon_Beaber I agree with you: “profound effect” is what they want to project to lure investment.

Fenebrutinib Update. Clinical Trial Results, Liver Disease, and Death: youtube.com/watch?v=xSFmZL…

@Brandon_Beaber It is the same target of eque-cel (CT103A), a drug cleared by the FDA to start trials in MS: iasobio.com/phone/info.php…

@ALFONFX It actually targets B-cell maturation antigen (BCMA) involved in the development of plasma cells (hence used to treat multiple myeloma), so I'm not sure this would work in MS.

@Brandon_Beaber can we trial this in a phase III in pMS? carvykti.com

@KiranDhamale77 @Brandon_Beaber As a rapidly-evolving PPMS patient, listening about ‘benign MS’ seems incredible

@Brandon_Beaber Please ppms cure

Invisible Symptoms in "Benign" Multiple Sclerosis youtube.com/shorts/MTyBgyB…

@RachelHorne19 @Brandon_Beaber I am now hopeful for anti-BCMA CAR-T cell therapy, given the meh results of BTKs. Hope I get to see some good results in the future !!

@Brandon_Beaber Tx for this... Be interesting to see what Roche have to say next month to explain the deaths. As someone on a B-cell depleter, I was hoping this drug might be the next one I was put on. Bit more reluctant now for obvious reasons.

My analysis of excess deaths with fenebrutinib in the FENhance 1/2 and FENtrepid trials suggests this would be extremely unlikely to occur by random chance. By X^2, p-value is 0.0016. By Fisher exact, p ~ 0.0019. But why?

@Brandon_Beaber Any info on PPMS? Why is this rarely prescribed?

Everyone is wrong! It's Imuran (azathioprine)! neurology.org/doi/pdfdirect/…

This drug reduced multiple sclerosis disability progression in a randomized trial but is very rarely prescribed. Can you guess what it is?

@Brandon_Beaber I usually assume rapidly-evolving, young PPMS is the “worst” in the MS spectrum, in relation to disability accrual. Not always, apparently.

Predictors of worsening disability in multiple sclerosis: being older, having other autoimmune diseases, more disability at baseline, low physical activity, being overweight/obese, smoking, low sun exposure (data from 3567 individuals with newly diagnosed with MS in Sweden).

@Brandon_Beaber Guess the argument “pMS is the real MS” is true after all

@Brandon_Beaber I’d agree. I was d’xed with PPMS, haven’t got a single relapse. PIRA has been brutal since 2024, despite Ocrevus since 2019.

This analysis of the French MS registry suggests the superiority of highly effective disease modifying therapies in preventing disability progression is primarily due to suppression of relapses and new MRI lesions rather than "PIRA" pubmed.ncbi.nlm.nih.gov/41689266/

ChatGPT answering the question, "create a caricature of me and my job based on everything you know about me." Somehow it thinks I'm rich and play dungeons and dragons.

Majestic in defeat, defiant in silence — you’re not done yet.

@Brandon_Beaber For inactive, young PPMS, that doesn’t seem to be the case 😣. So sad & scary to be on this side of the spectrum…

MS Prognosis is Improving Over Time youtube.com/shorts/5ghnYsE…

@Brandon_Beaber Wish all my academic achievements would save me from my rapidly evolving, non- active, young-onset PPMS, now going EDSS > 6. Good that when I was younger I was blissfully unaware of what would come 🤪

Higher level of education is associated with a better multiple sclerosis prognosis on average. Image is survival curve for NOT requiring an assistive device for mobility (EDSS 6.0) pubmed.ncbi.nlm.nih.gov/41529659/

@SpringerIME CAR-T cell therapies for B-cell malignancies should be studied in progressive multiple sclerosis also.

How well do you know CAR-T therapy? Following ASH 2025 in December, we're testing your clinical insight. What is the biggest advantage of rapid CAR-T manufacturing platforms for LBCL?

@Benbiotechrese1 @Brandon_Beaber True that

@Brandon_Beaber @ALFONFX Why would a neurologist prescribe a BTK like fenebrutinib for RMS when there is clearly a liver risk when excellent safe options already exist? I don’t see FDA taking that risk. Then for PPMS there is still a high unmet need but fenebrutinib was only similar to safer ocrevus

The FDA explains its rejection of the multiple sclerosis drug tolebrutinib in a Complete Response Letter (CRL). "A favorable benefit-risk profile could not be established for any patient subpopulation" download.open.fda.gov/crl/CRL_NDA219…

@Brandon_Beaber I always wonder how is it possible the treatment of certain types of leukemia and MS look similar. From rituximab to ibrutinib, from ocrelizumab to BTKs. Common ground? Could it be EBV? #KickEBVout

The Australian STOP-MS will evaluate the drugs spironolactone and famciclovir (which inhibit EBV replication in basic science studies) to prevent disability progression in MS. pubmed.ncbi.nlm.nih.gov/41450528/